Malignant mast cell neoplasm

Also known as: Malignant Mast Cell Tumors / Leukemia, Mast Cell / Mast Cell Leukemia / Mast Cell Leukemia (MCL) / Malignant-mast cell tumours / Aggressive systemic mastocytosis / Mast-Cell Sarcoma

DrugDrug NameDrug Description
DB06595MidostaurinMidostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors [A19108]. It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
DrugDrug NamePhaseStatusCount
DB00091Cyclosporine1 / 2Active Not Recruiting1
DB01073Fludarabine1 / 2Active Not Recruiting1
DB00688Mycophenolate mofetil1 / 2Active Not Recruiting1
DB00087Alemtuzumab2Active Not Recruiting1
DB08870Brentuximab vedotin2Completed1
DB00091Cyclosporine2Active Not Recruiting1
DB01073Fludarabine2Active Not Recruiting1
DB00688Mycophenolate mofetil2Active Not Recruiting1
DB00091CyclosporineNot AvailableActive Not Recruiting1
DB00091CyclosporineNot AvailableCompleted1
DB01073FludarabineNot AvailableActive Not Recruiting1
DB01073FludarabineNot AvailableCompleted1
DB00529FoscarnetNot AvailableCompleted1
DB01004GanciclovirNot AvailableCompleted1
DB00688Mycophenolate mofetilNot AvailableActive Not Recruiting1
DB00688Mycophenolate mofetilNot AvailableCompleted1
DB01610ValganciclovirNot AvailableCompleted1